MLICM
LCTX icon

Metropolitan Life Insurance Company (MetLife)’s Lineage Cell Therapeutics LCTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,666
Closed -$2.47K – 1162
2024
Q1 		$2.47K Buy
+1,666
New +$1.89K ﹤0.01% 2282
2023
Q4 		– Sell
-7,125
Closed -$8.41K – 2370
2023
Q3 		$8.41K Hold
7,125
– – ﹤0.01% 2285
2023
Q2 		$10K Buy
+7,125
New +$9.85K ﹤0.01% 2297
2022
Q1 		– Sell
-17,572
Closed -$43.1K – 2484
2021
Q4 		$43.1K Sell
17,572
-1,506
-8% -$3.52K ﹤0.01% 2712
2021
Q3 		$48.1K Sell
19,078
-19,631
-51% -$50.4K ﹤0.01% 2766
2021
Q2 		$110K Buy
+38,709
New +$100K ﹤0.01% 2547
2017
Q4 		– Sell
-65,827
Closed -$164K – 2513
2017
Q3 		$164K Sell
65,827
-117
-0.2% -$290 ﹤0.01% 2357
2017
Q2 		$182K Hold
65,944
– – ﹤0.01% 2390
2017
Q1 		$199K Buy
65,944
+8,471
+15% +$24.1K ﹤0.01% 2270
2016
Q4 		$182K Sell
57,473
-8,935
-13% -$27.4K ﹤0.01% 2400
2016
Q3 		$227K Buy
+66,408
New +$183K ﹤0.01% 2254
2016
Q1 		– Sell
-56,003
Closed -$185K – 2519
2015
Q4 		$185K Buy
+56,003
New +$167K ﹤0.01% 2316
2015
Q2 		– Sell
-55,715
Closed -$223K – 2705
2015
Q1 		$223K Buy
+55,715
New +$193K ﹤0.01% 2010

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LCTX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 1,666 shares — an estimated $2.47K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LCTX in Q1 2015 and held it in 13 quarters. The position peaked at $227K in Q3 2016. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,666 Lineage Cell Therapeutics shares in Q2 2024, an estimated $2.47K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Lineage Cell Therapeutics position peaked at $227K in Q3 2016.
  • 113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.